712 North Inc. Expands Intellectual Property Portfolio with New USPTO Patent for OMA1/OPA1 Modulators

November 11, 2025 — 712 North Inc., a pre-clinical pharmaceutical company specializing in mitochondrial medicine, announced today that the United States Patent and Trademark Office (USPTO) has granted a new patent entitled “Tricyclic compounds with OMA1/OPA1 modulatory properties.”

The patent covers a novel class of small molecules designed to regulate the OMA1/OPA1 axis, a critical pathway governing mitochondrial health, cristae integrity, and cellular survival. This intellectual property further solidifies 712 North’s position as a leader in the development of precision therapies for diseases driven by mitochondrial dysfunction.

“The grant of this patent is another significant milestone in our mission to protect and restore neuronal function,” said said Dr. Marcel V. Alavi, CEO of 712 North.

712 North develops personalized mitochondrial medicines for patients with Alzheimer’s and other age-related diseases.

For more information, please visit www.712north.com.